Find a Clinical Trial | Tufts Medicine

Filter

Showing 1 - 10 out of 20

DEFENDO Long-Term Follow-Up Study

A long-term extension study to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 Neurotrophic Keratitis who enrolled in the DEFENDO Study

Neurotrophic keratitis

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

A Modified Ketogenic, Anti‐Inflammatory Diet for Patients with High‐Grade Gliomas

A Modified Ketogenic, Anti-Inflammatory Diet for Patients with High-Grade Gliomas

Glioblastoma

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

SEER-2

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

Neurotrophic keratitis

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

POETYK SjS-1

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome (POETYK SjS-1)

Sjogren's syndrome

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

BALATON

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Macular degeneration

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

Belvedere

A Phase IV, Multicenter, Open-label, Single-Arm study of the response to treatment after transition to the port delivery system with Ranibizumab (Susvimotom [Ranibizumab injection]) in patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than Ranibizumab.

Macular degeneration

All genders

50+

Recruiting now

Department of Ophthalmology

Learn more

The ImmuneSense Study

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma – The ImmuneSense Study

Glioblastoma

All genders

18-70

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

KPI-012-C-001

A Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants with Persistent Corneal Epithelial Defect (PCED)

Corneal disorders

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

Non-Interventional Fresh Tumor Tissue

Analysis Of Cell Count, Viability, And Of Fresh Newly Diagnosed Glioblastoma Tissue

Glioblastoma

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Learn more

Discovery

Discovery Approach to Ocular Hypertension

Glaucoma

All genders

No minimum age

Recruiting now

Department of Ophthalmology

Learn more